BeyondSpring, Inc. is a New Jersey-based biopharmaceutical company dedicated to revolutionizing cancer treatment through the development of innovative therapies. With a strong commitment to improving the lives of cancer patients, they are at the forefront of the rapidly evolving treatment landscape, offering first-in-class treatments that raise the standard of care and enhance clinical outcomes for millions in need.
Through their subsidiary, SEED Therapeutics, BeyondSpring focuses on developing novel molecular glues (MG) as part of their Targeted Protein Degradation (TPD 2.0) approach, aiming to deliver breakthrough therapeutics. Their relentless dedication to research and continuous product development, particularly in the field of immunotherapies, positions them as a persistent partner in the fight against cancer, instilling hope and paving the way for exciting new discoveries.
Generated from the website